Xilio Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences:
- Cowen 43rd Annual Healthcare Conference on Monday, March 6, 2023, at 9:10 a.m. ET as part of a discussion called Novel Immuno-Oncology (IO) Corporate Panel.
- Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, with a virtual presentation at 4:00 p.m. ET.
A live webcast of the presentations can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at . A replay of the webcasts will be archived on the website for 30 days following each presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting and follow us on Twitter () and LinkedIn ().
This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.
For Investor Inquiries:
Melissa Forst
Argot Partners
For Media Inquiries:
Julissa Viana
Vice President, Corporate Communications
